Moser Wealth Advisors LLC Buys 1,035 Shares of Novo Nordisk A/S (NYSE:NVO)

Moser Wealth Advisors LLC boosted its holdings in Novo Nordisk A/S (NYSE:NVO) by 8.5% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 13,258 shares of the company’s stock after purchasing an additional 1,035 shares during the quarter. Moser Wealth Advisors LLC’s holdings in Novo Nordisk A/S were worth $1,579,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. 1620 Investment Advisors Inc. bought a new position in Novo Nordisk A/S in the 2nd quarter worth approximately $25,000. Gilliland Jeter Wealth Management LLC boosted its stake in Novo Nordisk A/S by 200.0% in the 2nd quarter. Gilliland Jeter Wealth Management LLC now owns 180 shares of the company’s stock worth $26,000 after purchasing an additional 120 shares during the period. Strategic Investment Solutions Inc. IL bought a new position in Novo Nordisk A/S in the 2nd quarter worth approximately $25,000. Orion Capital Management LLC bought a new position in Novo Nordisk A/S in the 1st quarter worth approximately $26,000. Finally, Halpern Financial Inc. boosted its stake in Novo Nordisk A/S by 113.0% in the 2nd quarter. Halpern Financial Inc. now owns 213 shares of the company’s stock worth $30,000 after purchasing an additional 113 shares during the period. 11.54% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research firms have weighed in on NVO. BMO Capital Markets dropped their price target on Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating for the company in a research note on Thursday, October 17th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. Finally, StockNews.com raised Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a report on Friday, November 1st. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $144.50.

Novo Nordisk A/S Stock Down 1.9 %

Shares of NVO opened at $107.05 on Wednesday. The company has a market cap of $480.39 billion, a PE ratio of 34.64, a P/E/G ratio of 1.32 and a beta of 0.42. The business has a fifty day moving average of $120.82 and a 200 day moving average of $130.22. Novo Nordisk A/S has a 52-week low of $94.73 and a 52-week high of $148.15. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.43.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.